0001213900-26-037664
SEC filingVaso Corporation’s FY2025 results delivered modest revenue growth and improved profitability, offset by a reported GAAP operating loss for the period.
The company reported a GAAP operating loss of $2.9M for FY2025, compared to $285.0K in operating income for the prior fiscal year. Net income rose 65.0% year-over-year, with the improvement attributed to a higher income tax benefit and the gain recognized on the sale of VHC-IT during 2025. Diluted earnings per share remained flat year-over-year at $0.01 for the second consecutive fiscal year.
Vaso has financed its operations and investment activities through existing working capital, with net cash provided by operating activities coming in at $9.3M for FY2025. Management’s near and long-term strategic plans focus on two core priorities: first, effectively controlling operating costs amid the ongoing inflationary environment to preserve margin, and second, exploring options in public capital markets to improve liquidity for the company’s common stock. The company also notes that its current manufacturing capacity and warehouse facilities are sufficient to meet foreseeable demand for its medical device products.